Inactive Instrument

Aimmune Therapeutics, Inc.

Equities

AIMT

US00900T1079

Biotechnology & Medical Research

Stephen Dilly Plans to Retire as CEO of Aimmune Therapeutics, Inc by the End of 2018

November 06, 2017 at 08:30 am EST

Aimmune Therapeutics, Inc. announced that CEO Stephen Dilly, M.B.B.S., Ph.D., plans to retire by the end of 2018. Dr. Dilly will continue as Aimmune’s CEO until his replacement joins the company and will be available through a transition period.

Latest news about Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc. to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIAÂ« [Peanut (Arachis Hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years	22-11-10	CI
Allergy Partners Announces Strategic Collaboration with Aimmune Therapeutics, Inc. to Provide PALFORZIA® Directly to Patients	22-10-13	CI
Aimmune Therapeutics, Inc. Announces Publication of Pooled Safety Analysis of PALFORZIA® Treatment for Up to 2 Years in the Journal of Allergy and Clinical Immunology	22-02-16	CI
Aimmune Therapeutics, Inc. Presents New PALFORZIA?	21-11-12	CI
Aimmune Therapeutics Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis	21-06-08	CI
Aimmune Therapeutics Announces New Clinical Data from A Pooled Analysis of Three Controlled Phase 3	21-02-25	CI
European Commission Approves Aimmune’S Palforzia as First-Ever Treatment for Peanut Allergy in the EU	20-12-21	CI
Nestle S A : shrugs off COVID-19 impact thanks to pet food and health nutrition	20-10-21	RE
Aimmune Therapeutics, Inc. Announces Executive Changes	20-10-19	CI
Aimmune Therapeutics, Inc. Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe	20-10-16	CI
Aimmune Therapeutics, Inc. Appoints Andrew Oxtoby as President	20-10-14	CI
Aimmune Therapeutics, Inc. Appoints Andrew Oxtoby as CEO	20-10-14	CI
GLOBAL MARKETS LIVE: U.S. banks beat expectations	20-10-13
Aimmune Therapeutics : Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With Subsidiary	20-10-13	DJ
Aimmune Therapeutics : shareholders accept $2 billion Nestle tender offer	20-10-13	RE
Aimmune Therapeutics, Inc.(NasdaqGM:AIMT) dropped from Russell Small Cap Comp Growth Index	20-10-13	CI
Aimmune Therapeutics, Inc.(NasdaqGM:AIMT) dropped from Russell 3000 Growth Index	20-10-13	CI
Aimmune Therapeutics, Inc.(NasdaqGM:AIMT) dropped from Russell 2000 Index	20-10-13	CI
Aimmune Therapeutics, Inc.(NasdaqGM:AIMT) dropped from Russell 2000 Growth Index	20-10-13	CI
Aimmune Therapeutics, Inc.(NasdaqGM:AIMT) dropped from Russell 3000 Index	20-10-13	CI
Aimmune Therapeutics, Inc.(NasdaqGM:AIMT) dropped from Russell 2500 Index	20-10-13	CI
Aimmune Therapeutics, Inc.(NasdaqGM:AIMT) dropped from Russell 2500 Growth Index	20-10-13	CI
Aimmune Therapeutics, Inc.(NasdaqGM:AIMT) dropped from Russell Small Cap Completeness Index	20-10-13	CI
Aimmune Therapeutics, Inc.(NasdaqGM:AIMT) dropped from Russell 2500 Growth-Dynamic Index	20-10-13	CI
Aimmune Therapeutics, Inc.(NasdaqGM:AIMT) dropped from Russell 2500 Dynamic Index	20-10-13	CI

Chart Aimmune Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT. PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that occurs with accidental exposure to peanut. PALFORZIA is to be used in conjunction with a peanut-avoidant diet. Its subsidiaries include Aimmune Therapeutics UK Limited, Aimmune Therapeutics (Bermuda) Ltd., Aimmune Therapeutics Netherlands Cooperatief U.A., Aimmune Therapeutics Netherlands B.V., Aimmune Therapeutics Ireland Limited and Aimmune Therapeutics Germany GmbH.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.73%	115B
REGENERON PHARMACEUTICALS, INC.	+13.29%	107B
BIONTECH SE	-13.68%	22.31B
ARGENX SE	-3.67%	21.6B
BEIGENE, LTD.	-5.96%	18.23B
WUXI APPTEC CO., LTD.	-39.93%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.38%	14.26B
SAREPTA THERAPEUTICS, INC.	+34.01%	12.37B
LEGEND BIOTECH CORPORATION	-27.69%	8.28B

Bio Therapeutic Drugs